Adr ratio change effective

July 31, 2025 biodexa pharmaceuticals plc (“biodexa” or the “company”) adr ratio change effective adss outstanding post ratio change biodexa pharmaceuticals plc (nasdaq: bdrx), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announces the previously announced ratio change of its american depositary receipts (“adr”) from one (1) adr representing ten thousand (10,000) ordinary shares, to the new ratio of one (1) adr representing one hundred thousand (100,000) ordinary shares (the "ratio change"), became effective at the open of business on july 31, 2025 (u.s. eastern time).  for adr holders, the ratio change will have the same effect as a one-for-ten reverse adr split.
BDRX Ratings Summary
BDRX Quant Ranking